ArticleVaccine2020
Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply.
Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 59 citations in OpenAlex.
- Safety and Immunogenicity of the ConvacellVaccines · 2024Article
- Fair-split distribution of multi-dose vaccines with prioritized age groups and dynamic demand: The case study of COVID-19.European journal of operational research · 2023Article
- Article
- Global pattern and determinants of coronavirus disease 2019 (COVID-19) vaccine coverage and progression: a global ecological study.Global health journal (Amsterdam, Netherlands) · 2023Article
- Acceptance and accessibility to the early phase COVID-19 vaccination among the healthcare workers and hill tribe population in Thailand.Scientific reports · 2022Article
- Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review.Immunologic research · 2022Review
- Anti-coronavirus vaccines will not accelerate the transition of humanity to a non-pandemic period, but the pandemic will take fewer victims.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.Pharmaceutics · 2022Review
- The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines.Vaccines · 2022Review
- Article
- SARS-CoV-2 variants and environmental effects of lockdowns, masks and vaccination: a review.Environmental chemistry letters · 2022Review
- A multi-echelon dynamic cold chain for managing vaccine distribution.Transportation research. Part E, Logistics and transportation review · 2021Article
- The Immunopathobiology of SARS-CoV-2 Infection.FEMS microbiology reviews · 2021Article
- COVID-19 pandemics Stage II - Energy and environmental impacts of vaccination.Renewable & sustainable energy reviews · 2021Review
- Challenges to COVID-19 vaccine supply chain: Implications for sustainable development goals.International journal of production economics · 2021Article
- Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.Vaccine · 2021Article
- Article
- Policy innovation and emergence of innovative health technology: The system dynamics modelling of early COVID-19 handling in Indonesia.Technology in society · 2021Article
- A multi-layer model for the early detection of COVID-19.Journal of the Royal Society, Interface · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization declared the COVID-19 disease as a pandemic requiring a rapid response. Through online search, direct communication with network members and an internal survey, engagements of developing countries' vaccine manufacturers' network members in the research and development of COVID-19 vaccines and their capacities in the manufacturing, fill-finish and distribution of vaccines were assessed. Currently, 19 network members engaged in research and development of COVID-19 vaccines, using six principal technology platforms. In addition, an internal survey showed that the number of vaccines supplied collectively by 37 members, in 2018-19, was about 3.5 billion doses annually. Almost a third of network members having vaccines prequalified by the World Health Organization comply with international regulations and mechanisms to distribute vaccines across borders. The use of existing manufacturing, fill-finish and distribution capabilities can support an efficient roll-out of vaccines against COVID-19, while maintaining supply security of existing vaccines for on-going immunization programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.